3/24
12:32 am
drts
Alpha Tau Medical: 2026 Is The Breakthrough Year [Seeking Alpha]
Low
Report
Alpha Tau Medical: 2026 Is The Breakthrough Year [Seeking Alpha]
3/19
08:10 pm
drts
Alpha Tau Medical Conference: Japan Approval, Rolling FDA PMA, and Big 2026 Data Readouts Teased [Yahoo! Finance]
Medium
Report
Alpha Tau Medical Conference: Japan Approval, Rolling FDA PMA, and Big 2026 Data Readouts Teased [Yahoo! Finance]
3/16
10:34 am
drts
Alpha Tau to Present at Sidoti March Virtual Small Cap Conference [Yahoo! Finance]
Neutral
Report
Alpha Tau to Present at Sidoti March Virtual Small Cap Conference [Yahoo! Finance]
3/16
10:02 am
drts
Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
Low
Report
Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
3/11
11:53 am
drts
Alpha Tau Medical (DRTS) had its price target raised by Citigroup Inc. from $7.00 to $9.00. They now have a "buy" rating on the stock.
Medium
Report
Alpha Tau Medical (DRTS) had its price target raised by Citigroup Inc. from $7.00 to $9.00. They now have a "buy" rating on the stock.
3/10
12:34 pm
drts
Alpha Tau Medical (DRTS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $12.00 price target on the stock.
Low
Report
Alpha Tau Medical (DRTS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $12.00 price target on the stock.
3/9
05:00 pm
drts
Alpha Tau Medical GAAP EPS of -$0.42 [Seeking Alpha]
Low
Report
Alpha Tau Medical GAAP EPS of -$0.42 [Seeking Alpha]
3/9
04:23 pm
drts
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/9
04:02 pm
drts
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
Medium
Report
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
3/4
08:00 am
drts
Alpha Tau Medical (DRTS) had its "neutral" rating reaffirmed by Piper Sandler. They now have a $5.00 price target on the stock.
Low
Report
Alpha Tau Medical (DRTS) had its "neutral" rating reaffirmed by Piper Sandler. They now have a $5.00 price target on the stock.
2/24
11:06 am
drts
Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
2/24
09:00 am
drts
Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
Low
Report
Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
2/19
07:26 am
drts
Alpha Tau Medical (NASDAQ:DRTS) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Low
Report
Alpha Tau Medical (NASDAQ:DRTS) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
1/29
09:00 am
drts
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
Medium
Report
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
1/28
09:57 am
drts
Taiho Oncology Appoints Peter Melnyk as President & Chief Executive Officer [Yahoo! Finance]
Medium
Report
Taiho Oncology Appoints Peter Melnyk as President & Chief Executive Officer [Yahoo! Finance]
1/23
03:40 am
drts
Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026 [Seeking Alpha]
Medium
Report
Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026 [Seeking Alpha]
1/21
06:19 am
drts
Alpha Tau Medical (NASDAQ:DRTS) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Alpha Tau Medical (NASDAQ:DRTS) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/8
07:01 am
drts
Wall Street Breakfast Podcast: Selloff To Surge In Defense [Seeking Alpha]
Medium
Report
Wall Street Breakfast Podcast: Selloff To Surge In Defense [Seeking Alpha]
1/6
10:56 am
drts
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study [Yahoo! Finance]
Medium
Report
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study [Yahoo! Finance]
1/6
09:00 am
drts
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
High
Report
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
1/6
01:48 am
drts
Throwing Precision Darts: The Company Leading Next Evolution of Cancer Radiation [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Throwing Precision Darts: The Company Leading Next Evolution of Cancer Radiation [Globe and Mail, The (Toronto, Canada)]
1/5
09:15 am
drts
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) [Yahoo! Finance]
Low
Report
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) [Yahoo! Finance]
1/5
09:00 am
drts
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
Medium
Report
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)